Seòmar agus comataidhean

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

Written questions must be answered within 10 working days (20 working days during recess)
Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Criathragan Hide all filters

Displaying 576 questions Show Answers

Order by |

Question reference: S5W-04932

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Wednesday, 23 November 2016
Current Status: Answered by Shona Robison on 30 November 2016

To ask the Scottish Government, further to the answer to question S5W-02025 by Shona Robison on 15 September 2016, what steps it has introduced to reduce the risk of future similar litigation regarding informed consent procedures.

The case in question resulted from a medical procedure that was carried out in 1999 and it is recognised that medical practice has advanced significantly in this time. Patients are now better informed and advised of the risks and complications regarding their medical treatment.

As I outlined in my answer to questions S5W-02025 and S5W-04657 on 25 November 2016, I expect all NHS boards and their clinicians to adhere to the long established General Medical Council guidance and to have robust clinical governance arrangements in place to ensure that the principles and framework contained in the guidance are applied by all doctors when seeking informed consent to treatment from patients.

The guidance advocates an approach of patients and doctors making decisions together, an approach which was endorsed by the court ruling in 2015.

All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at: http://www.parliament.scot/parliamentarybusiness/28877.aspx

Question reference: S5F-00580

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Monday, 28 November 2016
Current Status: Taken in the Chamber on 1 December 2016

To ask the First Minister what steps the Scottish Government is taking to address workforce issues in the NHS.

Question reference: S5W-04697

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Monday, 14 November 2016
Current Status: Answered by Shona Robison on 24 November 2016

To ask the Scottish Government what assessment it has made of the Scottish Medicines Consortium's decision not to recommend nivolumab for use by patients with advanced renal cell carcinoma.

Question reference: S5W-04698

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Monday, 14 November 2016
Current Status: Answered by Shona Robison on 24 November 2016

To ask the Scottish Government, in light of the Scottish Medicines Consortium's decision not to recommend nivolumab for use by patients with advanced renal cell carcinoma, what options it is considering to make this treatment available.

Question reference: S5O-00416

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Wednesday, 23 November 2016
Current Status: Taken in the Chamber on 1 December 2016

To ask the Scottish Government when the Minister for Transport and the Islands last met ScotRail and what issues were discussed.

Question reference: S5W-04718

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Tuesday, 15 November 2016
Current Status: Answered by Aileen Campbell on 23 November 2016

To ask the Scottish Government what the costs would be for introducing a gender-neutral human papillomavirus (HPV) vaccination programme.

It is not possible to know what the costs of a gender neutral HPV vaccination programme would be until the JCVI has made its final recommendation, as this will determine the eligibility group to be vaccinated, and potentially the vaccine product to be used.

Modelling work to look at the impact and cost effectiveness of such a programme is currently being undertaken by Public Health England and is expected to report in early 2017. Following this, and once all the necessary evidence is available, the JCVI will begin its deliberations on extending the HPV vaccination programme to adolescent boys.

The Scottish Government will of course carefully consider any future recommendations made by the JCVI on HPV vaccination.

Question reference: S5W-04713

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Tuesday, 15 November 2016
Current Status: Answered by Aileen Campbell on 23 November 2016

To ask the Scottish Government for what reason some NHS boards are treating people who have the hepatitis C virus according to national treatment targets while others are treating within a medicine budget.

NHS Boards are responsible for the clinical care of their local population and for making decisions on the use of their allocated budgets. It is for NHS Boards to assess the needs of their local population and deliver services accordingly. In the case of hepatitis C the incidence and prevalence of the disease varies across Scotland as does the distribution of genotypes of the disease. This means the scale and nature of hepatitis C infection in different Boards can necessitate a different response. The treatment target set by Scottish Government is a national target, and this target that has been met or exceeded each year.

Question reference: S5W-04717

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Tuesday, 15 November 2016
Current Status: Answered by Aileen Campbell on 23 November 2016

To ask the Scottish Government when it expects to be in a position to implement a human papillomavirus (HPV) vaccination programme for boys.

Question reference: S5W-04715

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Tuesday, 15 November 2016
Current Status: Answered by Aileen Campbell on 23 November 2016

To ask the Scottish Government what action it is taking to ensure that NHS boards optimise the savings from discounted medicines to treat more people who have the hepatitis C virus.

Question reference: S5W-04712

Asked by: Anas Sarwar, MSP for Glasgow, Scottish Labour
Date lodged: Tuesday, 15 November 2016
Current Status: Answered by Aileen Campbell on 23 November 2016

To ask the Scottish Government for what reason the national treatment target for the hepatitis C virus (HCV) remained the same for 2016-17 when the cost of HCV medicines has reportdly reduced due to savings made in the tendering process.

The treatment target is based on advice from the Treatment and Therapies sub-group. This group includes representatives from Health Protection Scotland, NHS Boards, National Procurement and patient representatives. Targets for 2016-17 were considered at a point when the treatment landscape was developing rapidly and during a period of high treatment demand. The group felt that in this context maintaining the target for a further year would provide the most stability to NHS Boards, but that the target should reviewed again for 2017-18. The national treatment target is a minimum target only and treatment numbers in 2016-17 are currently forecast to be 1871. This compares with 1724 treatments in 2015-16.